Revista nº 812

Piñeiro Silva C. | Terapia génica suicida contra el cáncer Actual Med. 2021; 106(812): 54- 65 63 modified by retroviral gene transduction. N Engl J Med. 1990;323(9):570-8. DOI: 10.1056/NEJM199008303230904 4. Raza A, Ghosh SS. Connexin-43 Enhances the Redesigned Cytosine Deaminase Activity for Suicide Gene Therapy in Human Breast Cancer Cells. Biochem Insights. 2019;12:1- 8. DOI:  10.1177/1178626418818182 5. Bennett EM, Anand R, Allan PW, et al. Designer gene the- rapy using an Escherichia coli purine nucleoside phos- phorylase/prodrug system. Chem Biol. 2003;10(12):1173- 81. DOI:  10.1016/j.chembiol.2003.11.008 6. Duzgunes N. Suicide Gene Therapy: Methods and Proto- cols. 1 ed. New York: Humana Press; 2019. 190 p. 7. Lee M, Kim Y-S, Lee K, et al. Novel Semi-Replicative Re- troviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblasto- ma Models. Cancers. 2019;11(8):1090. DOI:  10.3390/can- cers11081090 8. Zweiri J, Christmas SE. Demonstration of anti-tumour bystander killing with prodrug-preloaded suicide gene-en- gineered tumour cells: a potential improvement for can- cer therapeutics. Cancer cell international. 2020;20:26-. DOI:  10.1186/s12935-020-1115-4 9. Li J, Li H, Zhu L, et al. The adenovirus-mediated lina- marase/linamarin suicide system: A potential stra- tegy for the treatment of hepatocellular carcinoma. Cancer Lett. 2010;289(2):217-27. DOI:  10.1016/j.can- let.2009.08.016 10. Jang SJ, Kang JH, Lee TS, et al. Prodrug-activating Gene Therapy with Rabbit Cytochrome P450 4B1/4-Ipomeanol or 2-Aminoanthracene System in Glioma Cells. Nucl Med Mol Imaging. 2010;44(3):193-8. DOI:  10.1007/s13139- 010-0038-8 11. Tupper J, Stratford MR, Hill S, Tozer GM, Dachs GU. In vivo characterization of horseradish peroxidase with indo- le-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer. Cancer Gene Ther. 2010;17(6):420-8. DOI:  10.1038/cgt.2009.86 12. Ardiani A, Sanchez-Bonilla M, Black ME. Fusion enzymes containing HSV-1 thymidine kinase mutants and guan- ylate kinase enhance prodrug sensitivity in vitro and in vivo. Cancer Gene Ther. 2010;17(2):86-96. DOI:  10.1038/ cgt.2009.60 13. Ilsley DD, Lee S-H, Miller WH, Kuchta RD. Acyclic Guano- sine Analogs Inhibit DNA Polymerases .alpha., .delta., and .epsilon. with Very Different Potencies and Have Unique Mechanisms of Action. Biochemistry. 1995;34(8):2504-10. DOI:  10.1021/bi00008a014 14. Preuss E, Muik A, Weber K, Otte J, von Laer D, Fehse B. Cancer suicide gene therapy with TK.007: superior ki- lling efficiency and bystander effect. J Mol Med (Berl). 2011;89(11):1113-24. DOI:  10.1007/s00109-011-0777-8 15. Warren TD, Patel K, Rivera JL, Eshleman JR, Ostermeier M. Comprehensive mutagenesis on yeast cytosine dea- minase yields improvements in 5-fluorocytosine toxicity in HT1080 cells. AIChE Journal. 2020;66(3):e16688. DOI: 10.1002/aic.16688 16. Güngör T, Önder FC, Tokay E, et al. Prodrugs for nitrore- ductase based cancer therapy- 2: Novel amide/Ntr com- binations targeting PC3 cancer cells. Eur J Med Chem. 2019;171:383-400. DOI:  10.1016/j.ejmech.2019.03.035 17. Green LK, Storey MA, Williams EM, et al. The Flavin Re- ductase MsuE Is a Novel Nitroreductase that Can Effi- ciently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy. Cancers. 2013;5(3):985-97. DOI:  10.3390/cancers5030985 18. Rich MH, Sharrock AV, Hall KR, Ackerley DF, MacKichan JK. Evaluation of NfsA-like nitroreductases from Neisseria meningitidis and Bartonella henselae for enzyme-prod- rug therapy, targeted cellular ablation, and dinitrotolu- ene bioremediation. Biotechnol Lett. 2018;40(2):359-67. DOI:  10.1007/s10529-017-2472-5 19. Swe PM, Copp JN, Green LK, et al. Targeted mutagene- sis of the Vibrio fischeri flavin reductase FRase I to im- prove activation of the anticancer prodrug CB1954. Bi- ochem Pharmacol. 2012;84(6):775-83. DOI:  10.1016/j. bcp.2012.07.002 20. Williams EM, Rich MH, Mowday AM, et al. Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy. Biochemistry. 2019;58(35):3700-10. DOI:  10.1021/acs.biochem.9b00376 21. Parker WB, Allan PW, Waud WR, Hong JS, Sorscher EJ. Ef- fect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase. Cancer Gene Ther. 2011;18(6):390-8. DOI:  10.1038/cgt.2011.4 22. Parker WB, Allan PW, Ealick SE, et al. Design and evalu- ation of 5’-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant. Nucle- osides Nucleotides Nucleic Acids. 2005;24(5-7):387-92. DOI:  10.1081/ncn-200059807 23. Parker WB, Allan PW, Waud WR, et al. The use of Tricho- monas vaginalis purine nucleoside phosphorylase to acti- vate fludarabine in the treatment of solid tumors. Cancer Chemother Pharmacol. 2020;85(3):573-83. DOI:  10.1007/ s00280-019-04018-7 24. Afshar S, Asai T, Morrison SL. Humanized ADEPT com- prised of an engineered human purine nucleoside phos- phorylase and a tumor targeting peptide for treatment of cancer. Molecular cancer therapeutics. 2009;8(1):185-93. DOI:  10.1158/1535-7163.MCT-08-0652 25. Pahle J, Menzel L, Niesler N, et al. Rapid eradication of colon carcinoma by Clostridium perfringens Enterotox-